secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069156
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing
--------------------------------------------------------------------

- Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.
- Cash and short-term investments $263.7M; runway into H2 2026.
- FDA meeting for tanruprubart (ANX005) in GBS scheduled Q2 2025; open-label FORWARD study starting Q2 2025; BLA submission planned.
- Phase 3 ARCHER II for ANX007 in dry AMD with GA enrollment completion expected Q3 2025; top line data H2 2026.
- Proof-of-concept trial for oral C1s inhibitor ANX1502 in cold agglutinin disease anticipated completion mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025069156/0000950170-25-069156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017025069156/annx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer